BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Aratana Therapeutics (PETX) Announces Full Exercise Of Underwriters' Option to Purchase Additional Shares


1/30/2014 9:58:53 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

KANSAS CITY, Kan.
, Jan. 29, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing or acquisition, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, today announced the full exercise of the underwriters' option to purchase 975,000 additional shares of common stock in connection with the company's previously announced public offering of 6,500,000 shares of common stock. The additional shares are comprised of 150,000 shares of common stock being sold by Aratana and 825,000 shares of common stock being sold by a selling stockholder. With the exercise of the underwriters' option, gross proceeds to Aratana from the offering are expected to be $97.85 million, before deducting underwriting discounts and commissions and other offering expenses payable by Aratana Therapeutics.

Jefferies LLC, Barclays, and William Blair are acting as joint book-running managers for the offering. JMP Securities and Craig-Hallum Capital Group are acting as co-managers.

A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful.

The offering is being made only by means of a written prospectus forming part of the effective registration statement. Copies of the prospectus related to the offering may be obtained, when available, from Jefferies LLC, c/o Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th FL, New York, NY 10022, Prospectus_Department@Jefferies.com, (877) 547-6340; or Barclays, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, barclaysprospectus@broadridge.com, (888) 603-5847; or William Blair, Attention: Prospectus Department, 222 West Adams Street, Chicago, IL 60606, prospectus@williamblair.com, telephone: (800) 621-0687.

Contacts:
Tiberend Strategic Advisors, Inc.

Joshua Drumm, Ph.D.
jdrumm@tiberend.com; (212) 375-2664

Andrew Mielach
amielach@tiberend.com; (212) 375-2694

SOURCE Aratana Therapeutics, Inc.



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES